Literature DB >> 19109200

Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4.

Sofie Struyf1, Samuel Noppen, Tamara Loos, Anneleen Mortier, Mieke Gouwy, Hannelien Verbeke, Dana Huskens, Souphalone Luangsay, Marc Parmentier, Karel Geboes, Dominique Schols, Jo Van Damme, Paul Proost.   

Abstract

Posttranslational proteolytic processing of chemokines is a natural mechanism to regulate inflammation. In this study, we describe modification of the CXC chemokine stromal cell-derived factor 1alpha/CXCL12 by peptidylarginine deiminase (PAD) that converts arginine residues into citrulline (Cit), thereby reducing the number of positive charges. The three NH(2)-terminal arginines of CXCL12, Arg(8), Arg(12), and Arg(20), were citrullinated upon incubation with PAD. The physiologic relevance of citrullination was demonstrated by showing coexpression of CXCL12 and PAD in Crohn's disease. Three CXCL12 isoforms were synthesized for biologic characterization: CXCL12-1Cit, CXCL12-3Cit, and CXCL12-5Cit, in which Arg(8), Arg(8)/Arg(12)/Arg(20), or all five arginines were citrullinated, respectively. Replacement of only Arg(8) caused already impaired (30-fold reduction) CXCR4 binding and signaling (calcium mobilization, phosphorylation of ERK and protein kinase B) properties. Interaction with CXCR4 was completely abolished for CXCL12-3Cit and CXCL12-5Cit. However, the CXCR7-binding capacities of CXCL12-1Cit and CXCL12-3Cit were, respectively, intact and reduced, whereas CXCL12-5Cit failed to bind CXCR7. In chemotaxis assays with lymphocytes and monocytes, CXCL12-3Cit and CXCL12-5Cit were completely devoid of activity, whereas CXCL12-1Cit, albeit at higher concentrations than CXCL12, induced migration. The antiviral potency of CXCL12-1Cit was reduced compared with CXCL12 and CXCL12-3Cit and CXCL12-5Cit (maximal dose 200 nM) could not inhibit infection of lymphocytic MT-4 cells with the HIV-1 strains NL4.3 and HE. In conclusion, modification of CXCL12 by one Cit severely impaired the CXCR4-mediated biologic effects of this chemokine and maximally citrullinated CXCL12 was inactive. Therefore, PAD is a potent physiologic down-regulator of CXCL12 function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19109200     DOI: 10.4049/jimmunol.182.1.666

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo.

Authors:  Bashir M Mohamed; Navin K Verma; Anthony M Davies; Aoife McGowan; Kieran Crosbie-Staunton; Adriele Prina-Mello; Dermot Kelleher; Catherine H Botting; Corey P Causey; Paul R Thompson; Ger Jm Pruijn; Elena R Kisin; Alexey V Tkach; Anna A Shvedova; Yuri Volkov
Journal:  Nanomedicine (Lond)       Date:  2012-05-25       Impact factor: 5.307

2.  Does pharmacological dose of parenteral arginine have beneficial effect in rats with sub-acute peritonitis?

Authors:  Hui-Chen Lo; Shih-Chi Wu; Yao-Horng Wang; Chien-Hsing Lee
Journal:  Pediatr Surg Int       Date:  2010-02-24       Impact factor: 1.827

3.  The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1α function through distinct receptor interactions.

Authors:  Vikas Saini; Daniel M Staren; Joshua J Ziarek; Zayd N Nashaat; Edward M Campbell; Brian F Volkman; Adriano Marchese; Matthias Majetschak
Journal:  J Biol Chem       Date:  2011-07-13       Impact factor: 5.157

4.  The development of N-α-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-α-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.

Authors:  Corey P Causey; Justin E Jones; Jessica L Slack; Daisuke Kamei; Larry E Jones; Venkataraman Subramanian; Bryan Knuckley; Pedram Ebrahimi; Alexander A Chumanevich; Yuan Luo; Hiroshi Hashimoto; Mamoru Sato; Lorne J Hofseth; Paul R Thompson
Journal:  J Med Chem       Date:  2011-09-16       Impact factor: 7.446

5.  Inhibiting protein arginine deiminases has antioxidant consequences.

Authors:  Erin E Witalison; Xiangli Cui; Anne B Hofseth; Venkataraman Subramanian; Corey P Causey; Paul R Thompson; Lorne J Hofseth
Journal:  J Pharmacol Exp Ther       Date:  2015-01-29       Impact factor: 4.030

6.  N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis.

Authors:  Van C Willis; Alison M Gizinski; Nirmal K Banda; Corey P Causey; Bryan Knuckley; Kristen N Cordova; Yuan Luo; Brandt Levitt; Magdalena Glogowska; Piyanka Chandra; Liudmila Kulik; William H Robinson; William P Arend; Paul R Thompson; V Michael Holers
Journal:  J Immunol       Date:  2011-02-23       Impact factor: 5.422

Review 7.  The unique structural and functional features of CXCL12.

Authors:  Rik Janssens; Sofie Struyf; Paul Proost
Journal:  Cell Mol Immunol       Date:  2017-10-30       Impact factor: 11.530

8.  Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor.

Authors:  Alexander A Chumanevich; Corey P Causey; Bryan A Knuckley; Justin E Jones; Deepak Poudyal; Alena P Chumanevich; Tia Davis; Lydia E Matesic; Paul R Thompson; Lorne J Hofseth
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-03-17       Impact factor: 4.052

9.  Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.

Authors:  Sofie Struyf; Laura Salogni; Marie D Burdick; Jo Vandercappellen; Mieke Gouwy; Sam Noppen; Paul Proost; Ghislain Opdenakker; Marc Parmentier; Craig Gerard; Silvano Sozzani; Robert M Strieter; Jo Van Damme
Journal:  Blood       Date:  2010-10-27       Impact factor: 22.113

10.  Inactivation of epidermal growth factor by Porphyromonas gingivalis as a potential mechanism for periodontal tissue damage.

Authors:  Krzysztof Pyrc; Aleksandra Milewska; Tomasz Kantyka; Aneta Sroka; Katarzyna Maresz; Joanna Kozieł; Ky-Anh Nguyen; Jan J Enghild; Anders Dahl Knudsen; Jan Potempa
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.